Lightlake Therapeutics Inc. Expands Drug Development Capabilities by Appointing Mark Ellison, Ph.D., as Executive Vice President Development, Manufacturing and Quality
16 févr. 2016 09h00 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan® (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education
27 janv. 2016 09h00 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN® (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities
19 janv. 2016 09h00 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
Lightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of Pennsylvania
23 déc. 2015 09h00 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray
15 déc. 2015 09h00 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. (“Lightlake”) (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration
19 nov. 2015 08h30 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
Lightlake Therapeutics Inc. Receives Second Funding Commitment From a Prominent International Research and Development Foundation
01 oct. 2015 09h00 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...
Lightlake Therapeutics Inc. Announces FDA Accepts for Review Adapt Pharma Limited's NARCAN(R) (Naloxone Hydrochloride) Nasal Spray NDA and Grants Priority Review Status
25 sept. 2015 08h30 HE
|
Opiant Pharmaceuticals, Inc.
NEW YORK, Sept. 25, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB:LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use,...